Revenue
2019
2020
2021
2022
2023
2024
2025
4D Molecular Therapeutics, Inc. (FDMT)
Price$14.97Cached quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $85.2M | $37,000 | $20.7M | $3.1M | $18.0M | $13.4M | $7.0M |
| Research & development | $195.7M | $141.3M | $97.1M | $80.3M | $61.4M | $53.0M | $38.7M |
| Operating expenses | $244.8M | $187.9M | $133.6M | $113.2M | $89.4M | $70.3M | $57.8M |
| Operating income | −$159.5M | −$187.8M | −$112.9M | −$110.0M | −$71.3M | −$56.7M | −$50.8M |
| Operating margin | −187.24% | −507,678.38% | −544.65% | −3,516.52% | −395.46% | −424.04% | −729.37% |
| EBITDA | −$154.9M | −$183.2M | −$108.7M | −$107.6M | −$69.8M | −$55.2M | −$49.8M |
| EBITDA margin | −181.73% | −495,102.70% | −524.36% | −3,439.73% | −387.02% | −413.24% | −714.94% |
| Net income | −$140.1M | −$160.9M | −$100.8M | −$107.5M | −$71.3M | −$56.7M | −$49.3M |
| Net profit margin | −164.43% | −434,778.38% | −486.59% | −3,435.41% | −395.37% | −424.25% | −708.42% |
| Basic EPSper basic share | -$2.42 | -$2.98 | -$2.58 | -$3.32 | -$2.57 | -$8.82 | -$9.59 |
| Diluted EPSper diluted share | -$2.42 | -$2.98 | -$2.58 | -$3.32 | -$2.57 | -$8.82 | -$9.59 |
Owners
Reported shareholders
10.41%of listed shares
Jupiter Topco LLC5.75M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Jupiter Topco LLC | 10.41%5.75M shares |
RA CAPITAL MANAGEMENT, L.P. | 9.15%5.05M shares |
BlackRock, Inc. | 8.23%4.55M shares |
GOLDMAN SACHS GROUP INC | 7.71%4.26M shares |
NOVO HOLDINGS A/S | 5.88%3.25M shares |
STATE STREET CORP | 5.27%2.91M shares |
BVF INC/IL | 5.21%2.88M shares |
T. Rowe Price Investment Management, Inc. | 4.55%2.51M shares |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 4.07%2.25M shares |
Trails Edge Capital Partners, LP | 4.04%2.23M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.80%2.1M shares |
ARMISTICE CAPITAL, LLC | 3.62%2M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.04%1.13M shares |
BANK OF AMERICA CORP /DE/ | 2.03%1.12M shares |
Evergreen Quality Fund GP, Ltd. | 1.72%951.47K shares |
Parkman Healthcare Partners LLC | 1.72%948.18K shares |
Kirn David | ≈1.71%942.49K shares |
DIMENSIONAL FUND ADVISORS LP | 1.32%730.86K shares |
DEUTSCHE BANK AG\ | 1.29%710.94K shares |
CITADEL ADVISORS LLC | 1.25%687.6K shares |
Percentages use 55.21M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 23, 2026Form 4 · 10b5-1 | Bizily ScottChief Legal Officer | SellCommon Stock | 9.8K | $12.00 | $117.7K | 8.6K |
| Jun 22, 2026Form 4 · 10b5-1 | Kirn DavidSee Remarks | SellCommon Stock | 114.7K | $10.47 | $1.20M | 942.5K |
| Jun 1, 2026Form 4 · 10b5-1 | Kirn DavidSee Remarks | SellCommon Stock | 1.9K | $10.02 | $19.3K | 1.06M |
| Mar 20, 2026Form 4 | Gupta AshooVP, Finance and Controller | SellCommon Stock | 80 | $8.61 | $688.80 | 47.1K |
| Mar 20, 2026Form 4 | Gupta AshooVP, Finance and Controller | SellCommon Stock | 310 | $8.61 | $2.7K | 46.9K |